Generation of induced pluripotent stem cells (iPSCs) by somatic cell reprogramming involves global epigenetic remodelling 1 . Whereas several proteins are known to regulate chromatin marks associated with the distinct epigenetic states of cells before and after reprogramming 2,3 , the role of specific chromatin-modifying enzymes in reprogramming remains to be determined. To address how chromatin-modifying proteins influence reprogramming, we used short hairpin RNAs (shRNAs) to target genes in DNA and histone methylation pathways, and identified positive and negative modulators of iPSC generation. Whereas inhibition of the core components of the polycomb repressive complex 1 and 2, including the histone 3 lysine 27 methyltransferase EZH2, reduced reprogramming efficiency, suppression of SUV39H1, YY1 and DOT1L enhanced reprogramming. Specifically, inhibition of the H3K79 histone methyltransferase DOT1L by shRNA or a small molecule accelerated reprogramming, significantly increased the yield of iPSC colonies, and substituted for KLF4 and c-Myc (also known as MYC). Inhibition of DOT1L early in the reprogramming process is associated with a marked increase in two alternative factors, NANOG and LIN28, which play essential functional roles in the enhancement of reprogramming. Genome-wide analysis of H3K79me2 distribution revealed that fibroblast-specific genes associated with the epithelial to mesenchymal transition lose H3K79me2 in the initial phases of reprogramming. DOT1L inhibition facilitates the loss of this mark from genes that are fated to be repressed in the pluripotent state. These findings implicate specific chromatin-modifying enzymes as barriers to or facilitators of reprogramming, and demonstrate how modulation of chromatinmodifying enzymes can be exploited to more efficiently generate iPSCs with fewer exogenous transcription factors.
Generation of induced pluripotent stem cells (iPSCs) by somatic cell reprogramming involves global epigenetic remodelling 1 . Whereas several proteins are known to regulate chromatin marks associated with the distinct epigenetic states of cells before and after reprogramming 2, 3 , the role of specific chromatin-modifying enzymes in reprogramming remains to be determined. To address how chromatin-modifying proteins influence reprogramming, we used short hairpin RNAs (shRNAs) to target genes in DNA and histone methylation pathways, and identified positive and negative modulators of iPSC generation. Whereas inhibition of the core components of the polycomb repressive complex 1 and 2, including the histone 3 lysine 27 methyltransferase EZH2, reduced reprogramming efficiency, suppression of SUV39H1, YY1 and DOT1L enhanced reprogramming. Specifically, inhibition of the H3K79 histone methyltransferase DOT1L by shRNA or a small molecule accelerated reprogramming, significantly increased the yield of iPSC colonies, and substituted for KLF4 and c-Myc (also known as MYC). Inhibition of DOT1L early in the reprogramming process is associated with a marked increase in two alternative factors, NANOG and LIN28, which play essential functional roles in the enhancement of reprogramming. Genome-wide analysis of H3K79me2 distribution revealed that fibroblast-specific genes associated with the epithelial to mesenchymal transition lose H3K79me2 in the initial phases of reprogramming. DOT1L inhibition facilitates the loss of this mark from genes that are fated to be repressed in the pluripotent state. These findings implicate specific chromatin-modifying enzymes as barriers to or facilitators of reprogramming, and demonstrate how modulation of chromatinmodifying enzymes can be exploited to more efficiently generate iPSCs with fewer exogenous transcription factors.
To examine the influence of chromatin modifiers on somatic cell reprogramming, we used a loss-of-function approach to interrogate the role of 22 select genes in DNA and histone methylation pathways. We tested a pool of three hairpins for each of 22 target genes and observed knockdown efficiencies of .60% for 21 out of 22 targets ( Supplementary Fig. 1 ). We infected fibroblasts differentiated from the H1 human embryonic stem cell (ESC) line (dH1fs) with shRNA pools, transduced them with reprogramming vectors expressing OCT4 (also known as POU5F1), SOX2, KLF4 and c-Myc (OSKM), and identified the resulting iPSCs by Tra-1-60 staining ( Fig. 1a) 4 . Eight shRNA pools reduced reprogramming efficiency ( Fig. 1b) . Among the target genes were OCT4 (included as a control), and EHMT1 and SETDB1, two H3K9 methyltransferases whose histone mark is associated with transcriptional repression. The remaining five shRNA pools targeted components of polycomb repressive complexes (PRC), major mediators of gene silencing and heterochromatin formation 5 . Inhibition of PRC1 (BMI1, RING1) and PRC2 components (EZH2, EED, SUZ12) significantly decreased reprogramming efficiency while having negligible effects on cell proliferation ( Fig. 1c and Supplementary Fig. 2 ). This finding is of particular significance given that EZH2 is necessary for fusion-based reprogramming 6 and highlights the importance of transcriptional silencing of the somatic cell gene expression program during generation of iPSCs.
In contrast to genes whose functions seem to be required for reprogramming, inhibition of three genes enhanced reprogramming: YY1, SUV39H1 and DOT1L ( Fig. 1b, d ). YY1 is a context-dependent transcriptional activator or repressor 7 , whereas SUV39H1 is a histone H3K9 methyltransferase implicated in heterochromatin formation 8 . Interestingly, enzymes that modify H3K9 were associated with both inhibition and enhancement of reprogramming, which suggested that unravelling the mechanisms for their effects might be challenging. Thus, we focused on DOT1L, a histone H3 lysine 79 methyltransferase that has not previously been studied in the context of reprogramming 9 . We used two hairpin vectors that resulted in the most significant downregulation of DOT1L and concomitant decrease in global H3K79 methylation levels ( Supplementary Fig. 3a, b ). Fibroblasts expressing DOT1L shRNAs formed significantly more iPSC colonies when tested separately or in a context where they were fluorescently labelled and co-mixed with control cells ( Fig. 2a and Supplementary  Fig. 4 ). This enhanced reprogramming phenotype could be reversed by overexpressing an shRNA-resistant wild-type DOT1L, but not a catalytically inactive DOT1L, indicating that inhibition of catalytic activity of DOT1L is key to enhance reprogramming 10 ( Fig. 2a ). Our findings with dH1fs were applicable to other human fibroblasts, as IMR-90 and MRC-5 cells also showed threefold and sixfold increases in reprogramming efficiency, respectively, upon DOT1L suppression ( Supplementary Fig. 5 ). To validate our findings independently of shRNA-mediated knockdown, we used a recently discovered small molecule inhibitor of DOT1L catalytic activity. EPZ004777 (ref. 11, referred to as iDot1L) abrogated H3K79 methylation at concentrations ranging from 1 mM to 10 mM and increased reprogramming efficiency three-to fourfold ( Fig. 2b and Supplementary Fig. 6a, b ). Combination of inhibitor treatment with DOT1L knockdown did not further increase reprogramming efficiency, reinforcing our previous observation that inhibition of the catalytic activity of DOT1L is key to reprogramming ( Supplementary Fig. 6c ). iPSCs generated through DOT1L inhibition showed characteristic ESC morphology, immunoreactivity for SSEA4, SSEA3, Tra-1-81, OCT4 and NANOG, and differentiated into all three embryonic germ layers in vitro and in teratomas ( Supplementary Fig. 7a -c). Therefore, iPSCs generated following DOT1L inhibition display all of the hallmarks of pluripotency.
We next assessed DOT1L inhibition in murine reprogramming. iDot1L treatment led to threefold enhancement of reprogramming of mouse embryonic fibroblasts carrying an OCT4-GFP (green fluorescent protein) reporter gene (OCT4-GFP MEFs; Fig. 2c ). Reprogramming of tail-tip fibroblasts (TTFs) derived from a conditional knockout DOT1L mouse strain yielded significantly more iPSC colonies upon deletion of DOT1L 12 ( Supplementary Fig. 8a ). Cre-mediated excision of both floxed DOT1L alleles in iPSC clones derived from homozygous TTFs was confirmed by genomic PCR ( Supplementary Fig. 8b ). DOT1L inhibition also increased reprogramming efficiency of MEFs and peripheral blood cells derived from an inducible secondary iPSC mouse strain 13 ( Supplementary Fig. 8c, d ). Taken together, these results demonstrate that DOT1L inhibition enhances reprogramming of both mouse and human cells.
We next examined the cellular mechanisms by which DOT1L inhibition promotes reprogramming. DOT1L inhibition affected neither retroviral transgene expression nor cellular proliferation ( Supplementary Fig. 9a -c). Although previous studies indicated that DOT1L-null cells have increased apoptosis and accumulation of cells in G2 phase 9 , we failed to observe a significant increase in apoptosis or change in the cell cycle profile of DOT1L-inhibited fibroblasts ( Supplementary Fig. 9d, e ). In human iPSC clones derived from shDot1L fibroblasts, DOT1L inhibition was no longer evident, reflecting the known silencing of retroviruses that occurs during reprogramming ( Supplementary Fig. 10a ). Quantitative PCR (qPCR) analysis revealed that the silencing occurred by day 15 after OSKM transduction ( Supplementary Fig. 10b , c). To define the crucial time window for DOT1L inhibition, we treated fibroblasts with iDot1L at 1-week intervals during reprogramming. iDot1L treatment in either the first or second week was sufficient to enhance reprogramming, whereas treatment in the third week or a 5-day pretreatment had no effect ( Supplementary Fig. 10d , e). Immunofluorescence analysis revealed significantly greater numbers of Tra-1-60-positive cell clusters on day 10 and day 14 in shDot1L cultures ( Supplementary Fig. 11a, b) , indicating that the emergence of iPSCs is accelerated upon DOT1L inhibition. When we extended the reprogramming experiments by 10 more days, shDot1L cells still yielded more iPSC colonies than controls ( Supplementary Fig. 11c ). Taken together, these findings indicate that DOT1L inhibition acts in early to middle stages to accelerate and increase the efficiency of the reprogramming process.
To assess whether DOT1L inhibition could replace any of the reprogramming factors, we infected control and DOT1L-inhibited fibroblasts with three factors, omitting one factor at a time. In the absence of OCT4 or SOX2 no iPSC colonies emerged ( Fig. 2d ). When we omitted either KLF4 or c-Myc, DOT1L-inhibited fibroblasts gave rise to robust numbers of Tra-1-60-positive colonies, whereas control cells generated very few colonies, as reported previously 4 (Fig. 2d-f and Supplementary Fig. 12a ). Importantly, DOT1L-inhibited fibroblasts transduced with only OCT4 and SOX2 gave rise to Tra-1-60-positive colonies, whereas control fibroblasts did not ( Fig. 2d-f ). These twofactor iPSCs showed typical ESC morphology, silenced the reprogramming vectors and had all of the hallmarks of pluripotency as gauged by endogenous pluripotency factor expression and the ability to form all three embryonic germ layers in vitro and in teratomas (Supplementary 
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Figs 7a-c and 12b). PCR on genomic DNA isolated from expanded colonies confirmed the absence of integrated KLF4 and c-Myc transgenes ( Supplementary Fig. 12c ). Thus, we were able to generate twofactor iPSCs either by suppression of DOT1L expression or chemical inhibition of its methyltransferase activity.
To gain insights into the molecular mechanisms of how DOT1L inhibition promotes reprogramming and replaces KLF4 we performed global gene-expression analyses on control and shDot1L fibroblasts before and 6 days after OSKM and OSM transduction, along with cells that were treated with iDot1L. Relatively few genes were differentially expressed in shDot1L cells on day 6 of reprogramming (22 up, 23 down; Supplementary Table 3 ). Inhibitor-treated cells showed broader gene expression changes (405 up and 175 down; Supplementary Table 3) , presumably due to more complete inhibition of K79me2 levels (Fig. 3a) . In the absence of KLF4, 94 genes were differentially upregulated in shDot1L cells; intersection of this set of genes with the set differentially upregulated in four-factor reprogramming of DOT1L-inhibited cells yielded only five common genes (Fig. 3a, b ). We were particularly intrigued to find NANOG and LIN28 upregulated in all three instances of DOT1L inhibition, because these two genes are part of the core pluripotency network of human ESCs 14, 15 and can reprogram human fibroblasts into iPSCs when used in combination with OCT4 and SOX2 (ref. 16) .
We explored the possibility that NANOG and LIN28 upregulation might account for the enhanced reprogramming observed following DOT1L inhibition, and validated their upregulation in shDot1L fibroblasts upon OSM or OS transduction ( Supplementary Fig. 13a, b) . Interestingly, at this early time point REX1 (also known as ZFP42) and DNMT3B, two other well-characterized pluripotency genes, were not upregulated, indicating that DOT1L inhibition does not broadly upregulate the pluripotency network. Suppression of either Nanog or Lin28 abrogated the two-factor (OS) reprogramming of shDot1L fibroblasts, indicating the essential roles of NANOG and LIN28 in this process ( Fig. 3c and Supplementary Fig. 13c ). DOT1L inhibition also led to increased NANOG expression in the context of OCT4, SOX2 and LIN28 (OSL) and LIN28 expression in the context of OCT4, SOX2 and NANOG (OSN) ( Supplementary Fig. 14a ). Furthermore, DOT1L inhibition significantly increased the efficiency of three-factor reprogramming in the context of OSN and OSL ( Supplementary Fig. 14b ). Finally, inclusion of NANOG and LIN28 in the OSKM reprogramming cocktail did not confer any additional enhancement to shDot1L cells ( Fig. 4d and Supplementary Fig. 14c ). Taken together, these data implicate NANOG and LIN28 in the enhancement of reprogramming and replacement of KLF4 and c-Myc with DOT1L inhibition.
To gain insight into the genome-wide chromatin changes that are facilitated by DOT1L inhibition, we performed chromatin immunoprecipitation followed by DNA sequencing (ChIP-seq) for H3K79me2 and H3K27me3 in human ESCs as well as fibroblasts undergoing CDO1  CHST15  COL11A1  LEFTY1  LEFTY2  LIN28A  LUM  NANOG  PROM1  SCG2  UPP1   ARL6IP1  CADM1  INHBA  INHBB  LEFTY1  LIN28A  LUM  NANOG  NPPB  PMEPA1  RUNX3  UPP1   LEFTY1 LIN28A 
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reprogramming, with or without iDot1L treatment ( Supplementary  Fig. 15 ). In both ESCs and fibroblasts, H3K79me2 is positively associated with transcriptionally active genes and negatively associated with genes marked by H3K27me3 ( Supplementary Fig. 16a-c) . ESCspecific genes marked by H3K79me2 included pluripotency factors, a subset of their downstream targets, and genes involved in epithelial cell adhesion such as CDH1 (E-cadherin) (280 genes; Supplementary  Fig. 17a, b and Supplementary Tables 4, 5 ). In contrast, in fibroblasts, genes marked by H3K79me2 were significantly enriched in genes induced during the epithelial to mesenchymal transition (EMT) (377 genes; Supplementary Fig. 17a ).
Among the 348 genes that showed reduced H3K79me2 6 days after OSKM expression, we likewise found a significant enrichment of gene sets associated with the induction of a mesenchymal state, including SNAI2, TGFB2 and TGFBR1 ( Supplementary Fig. 18a) 17, 18 . Only a few of these genes showed decreased expression at day 6 (12 out of 348), but the vast majority of them lacked this mark in the pluripotent state (272 out of the 348 devoid of H3K79me2 in ESCs), suggesting they were destined for transcriptional silencing during reprogramming. This finding prompted us to ask whether DOT1L inhibition results in the removal of H3K79me2 from such fibroblast-specific, EMTassociated genes. Upon DOT1L inhibitor treatment, H3K79me2 levels were reduced on almost all loci, with the exception of a subset comprised mostly of housekeeping genes that also had high levels of H3K79me2 in ESCs ( Supplementary Fig. 19a) . Strikingly, the genes that lost proportionally the most H3K79me2 in inhibitor-treated fibroblasts during reprogramming (eightfold or more) were again highly enriched in genes induced in EMT ( Supplementary Fig. 19b ). Mesenchymal master regulators such as SNAI1, SNAI2, ZEB1, ZEB2 and TGFB2 were among these genes (Fig. 4a) 19 . In the presence of the DOT1L inhibitor, these regulators were more strongly repressed during reprogramming, whereas epithelial genes such as CDH1 and OCLN were more robustly upregulated (Fig. 4b) . The extinction of fibroblast gene expression was accompanied by increased deposition of the repressive H3K27me3 mark on the majority of fibroblastspecific regulators examined ( Supplementary Fig. 20) . In contrast, H3K27me3 was depleted to a greater extent on SOX2 and E-cadherin promoters, reflecting their activation during reprogramming. Finally, the H3K27me3 status of master regulators of other lineages, such as OLIG2, MYOD1, NKX2-1 and GATA4, remained unchanged upon DOT1L inhibitor treatment, indicating that the deposition of H3K27me3 was specific to fibroblast-specific regulators.
To test the functional importance of downregulation of mesenchymal regulators in the iDot1L-mediated enhancement of reprogramming, we overexpressed TWIST1, SNAI1 and ZEB1 or added soluble TGF-b2 to cells undergoing reprogramming in the presence of the DOT1L inhibitor. All of these perturbations significantly counteracted the enhancement observed with DOT1L inhibition (Fig. 4c) . Interestingly, expression of these factors also abrogated the iDot1L-mediated upregulation of NANOG and LIN28, suggesting that the effect of DOT1L LETTER RESEARCH inhibition on these two pluripotency genes is likely to be indirect ( Fig. 4d, e ). Conversely, we tested whether destabilization of the mesenchymal state by inhibition of TGF-b signalling would be redundant with DOT1L inhibition. A small molecule inhibitor of TGF-b signalling (SB431542) increased reprogramming efficiency, but in combination with the DOT1L inhibitor, showed no significant further increase in iPSC colonies ( Supplementary Fig. 21 ). Taken together these data indicate that in fibroblasts, downregulation of the mesenchymal gene expression program is critical to enhancement of reprogramming by DOT1L inhibition. Our loss-of-function survey indicates that chromatin-modifying enzymes play critical roles for both reactivating silenced loci as well as reinstating closed domains of heterochromatin during the global epigenetic remodelling of differentiated cells to pluripotency, thus implicating specific enzymes as facilitators or barriers to cell fate transitions. DOT1L inhibition seems to enhance reprogramming at least in part by facilitating loss of H3K79me2 from fibroblast genes whose silencing is required for reprogramming ( Supplementary Fig. 22 ). Interestingly, KLF4, which can be replaced by DOT1L inhibition, has been shown to facilitate a mesenchymal to epithelial transition (MET) by inducing E-cadherin expression 20 . Persistent H3K79me2 at the fibroblast master regulators during the initial phases of reprogramming seems to prevent shutdown of these genes, thus hindering the acquisition of an epithelial phenotype concomitant with delayed activation of NANOG and LIN28. In this regard H3K79me2 acts as a barrier to efficient repression of the somatic program by the reprogramming factors. This notion is consistent with the role of Dot1 in yeast, where it antagonizes gene repression 21 . As reprogramming of blood cells is also enhanced by DOT1L inhibition, we speculate that DOT1L inhibition may enhance reprogramming in a broad range of cell types by facilitating the silencing of lineage-specific programs of gene expression. Finally, our results also demonstrate that specific chromatin modifiers can be modulated to generate iPSCs more efficiently and with fewer exogenously introduced transcription factors.
METHODS SUMMARY
shRNAs were designed using the RNAi Codex 22 . 97-mer oligonucleotides (Supplementary Table 1 ) were PCR-amplified and cloned into the MSCV-PM 23 vector. Reprogramming assays were carried out with either retroviral 4 or lentiviral 16 reprogramming vectors. dH1f cells were previously described 4 . For gene expression analyses, total RNA was extracted from two or three independent culture plates for each condition and transcriptional profiling was performed using Affymetrix U133A microarrays. ChIP-seq was performed as described with slight modifications 12 .
